Nanocarrier-based targeting strategies in epilepsy: addressing pathophysiological barriers
Journal of Pharmacy and Pharmacology · 03.07.2026 · 78 (7)
DOI: 10.1093/jpp/rgag077 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 23.07.2026. Verfasst von Abhishek Chauhan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India. Hauptthemen laut MEDLINE: Epilepsy, Anticonvulsants, Drug Carriers, Drug Delivery Systems. Die Arbeit nennt 237 Literaturangaben.
Abstract (Originalsprache)
Objectives
Epilepsy is a chronic neurological disorder affecting nearly 50 million people worldwide and is characterized by recurrent seizures caused by abnormal neuronal activity. Conventional therapies, including antiepileptic drugs, growth factors, and gene therapy, are often limited by poor blood-brain barrier (BBB) penetration, drug resistance, adverse effects, and low bioavailability. This review summarizes recent advances in nanocarrier-based drug delivery systems for improving epilepsy treatment.
Methods
A comprehensive review of peer-reviewed articles, patents, and clinical studies was conducted to evaluate lipid-based, vesicular, polymeric, dendrimer, and inorganic nanocarriers. Their formulation strategies, BBB transport mechanisms, therapeutic applications, clinical progress, and future prospects were critically analysed. Key findings Nanocarriers enhance the solubility, stability, bioavailability, controlled release, and brain targeting of antiepileptic drugs. Liposomes, solid lipid nanoparticles, nanostructured lipid carriers, polymeric nanoparticles, dendrimers, nanoemulsions, and metallic nanoparticles have demonstrated improved BBB penetration, prolonged drug action, reduced toxicity, and enhanced seizure control in preclinical studies. Despite promising outcomes, challenges related to large-scale manufacturing, long-term safety, regulatory approval, and clinical translation remain.
Conclusions
Nanomedicine represents a promising approach for overcoming the limitations of conventional epilepsy therapy by enabling efficient brain-targeted drug delivery. Further optimization, safety evaluation, and clinical validation are essential to support the successful translation of nanocarrier-based therapies into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India.
ORCID-Profile: Ankit Awasthi, Rohit Bhatia
Zitieren
APA
Chauhan, A., Kumar, A., Awasthi, A., & Bhatia, R. (2026). Nanocarrier-based targeting strategies in epilepsy: addressing pathophysiological barriers. Journal of Pharmacy and Pharmacology, 78(7). https://doi.org/10.1093/jpp/rgag077
Vancouver
Chauhan A, Kumar A, Awasthi A, Bhatia R. Nanocarrier-based targeting strategies in epilepsy: addressing pathophysiological barriers. Journal of Pharmacy and Pharmacology. 2026;78(7). doi:10.1093/jpp/rgag077
BibTeX
@article{Chauhan2026,
author = {Chauhan, Abhishek and Kumar, Ankush and Awasthi, Ankit and Bhatia, Rohit},
title = {Nanocarrier-based targeting strategies in epilepsy: addressing pathophysiological barriers},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
volume = {78},
number = {7},
doi = {10.1093/jpp/rgag077}
}
EUVIMED